. 2019 Dec 10;6:291. doi: 10.3389/fmed.2019.00291

Table 3.

The MGE characteristics of patients with pSS and non-SS-MGD according medical history.

Variables		pSS (≤3y)	Non-SS-MGD (≤3y)	pSS (>3y)	Non-SS-MGD (>3y)
Female		26	27	23	25
Meibomian gland atrophy areas	OD	21.22 ± 12.33	20.15 ± 7.12	40.29 ± 12.33	21.65 ± 7.21^b
	OS	21.18 ± 13.02	20.21 ± 7.27	40.53 ± 13.02	22.76 ± 7.41^b
Lid margin score	OD	1.24 ± 0.72	1.18 ± 0.19	4.43 ± 0.72	1.34 ± 0.39^a
	OS	1.22 ± 0.68	1.11 ± 0.41	4.06 ± 0.68	1.33 ± 0.41^a
Expressible meibomian glands number	OD	4.09 ± 0.77	5.09 ± 0.87	2.25 ± 0.62	5.51 ± 0.90^a
	OS	4.02 ± 0.71	5.11 ± 0.87	2.28 ± 0.59	5.41 ± 0.89^a
Meibomian gland secretions quality	OD	4.61 ± 0.57	5.76 ± 1.12	2.11 ± 0.57	5.26 ± 0.98^a
	OS	4.55 ± 0.53	5.81 ± 1.13	2.13 ± 0.53	5.37 ± 1.01^a

Meibomian gland related examination in the patients with pSS compared to non-SS-related MGD. Values equal the mean ± SE. DED, dry eye disease; MGD, meibomian gland dysfunction; pSS, primary Sjögren syndrome; OSDI, Ocular Surface Disease Index.

^{a, b}

Significantly (^ap < 0.05, ^bp ≤ 0.01) greater than in the controls.